The Latest Breaking News from Viatris

Due to Viatris’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain cautious about the stock’s prospects.

Viatris is all set to announce its third-quarter results next month, with analysts predicting a double-digit decline in the company's earnings.

Viatris is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.85%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.16%. US stock indexes on Thursday settled higher, with the S&P 500 climbing to a...

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.13%. US stock indexes this morning are moderately higher, with the S&P 500 climbing...

The S&P 500 Index ($SPX ) (SPY ) this morning is down -0.04%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.27%. US stock indexes this morning are mixed, with the Dow Jones Industrials posing...

The growing demand for innovative drugs, the use of advanced technologies, and growing global healthcare needs boost the pharmaceutical industry’s long-term growth prospects. Therefore, fundamentally strong pharma stocks Viatris (VTRS), Wave Life Sciences (WVE), and MEI Pharma (MEIP) might be ideal additions to your portfolio. Read on.

The S&P 500 rebounded last week near record highs, but is up just 0.2% so far in 2024. These are the index's top performers so far.

Just when it looked like technology stocks took over the S&P 500 — another sector is on the rise.